Rosella sp. And application thereof

Through the antibacterial effect of Rothia nasimurium, the prevention and treatment problems of various drug-resistant bacteria were solved, and new application prospects were provided, especially for Streptococcus suis, Mycobacterium tuberculosis, and Abalone grapes Antibacterial effects of cocci, Corynebacterium desiccosis and Streptococcus non-lacticulatidosis.

CN118956647AActive Publication Date: 2024-11-15SHANDONG PROVINCIAL CENT FOR ANIMAL DISEASE CONTROL & PREVENTION
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410937303.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-11-15
Estimated Expiration
2044-09-14

AI Technical Summary

Technical Problem

In the prior art, there are few studies on the function and application of Rochelid, especially in the case of resistance to multiple drugs, it is difficult to find effective prevention and treatment options.

Method used

Provide a Rothia nasimurium, the deposit number is CGMCC No. 30097, which has antibacterial effect. Through its metabolites NRPS, betalactone, and lanthipetide secondary metabolic gene clusters, a drug with antibacterial effect is prepared to target Streptococcus swine , Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium sedatives, Streptococcus lactis and other bacteria.

Benefits of technology

For the first time, Rochetia has a significant antibacterial effect on the above bacteria, providing new application prospects and is convenient for relevant scientific research and drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956647A_ABST
    Figure CN118956647A_ABST
Patent Text Reader

Abstract

The invention discloses Roche and an application thereof, the Roche is Roche nossum, and is preserved in the China General Microbiological Culture Collection Center, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, 3 #, 1 # yard, West Beichen Road, Chaoyang District, Beijing, the preservation number is CGMCC No.30097, and the preservation time is March 22, 2024. The Rosella has a bacteriostatic effect on streptococcus suis, mycobacterium tuberculosis, staphylococcus aureus, corynebacterium drying and non-streptococcus lactis, and is convenient to be subsequently used for related scientific research.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, in particular to Roseburia and applications thereof. Background Art

[0002] Rothia nasalis is a common conditional pathogen. It is a symbiotic bacteria in the upper respiratory tract and intestines of pigs, humans and other mammals and poultry. However, in recent years, studies have found that the bacteria also have pathogenicity and are pathogenic to Arctic goose embryos, dog skin, ducks and other animals. Rothia is a Gram-positive bacterium that is facultatively anaerobic, does not form spores, and is non-motile. Currently, the genus contains six species, namely Rothia aeria, Rothia amarae, Rothia dentocariosa, Rothiamucilaginosa, Rothia nasimurium and Rothia terrae.

[0003] In 2020, ducks on a farm in Northeast my country developed sporadic respiratory symptoms such as runny nasal discharge, coughing, and shortness of breath, as well as reduced food intake and depression. In order to determine the cause of the disease and propose targeted prevention and treatment plans, nasal swabs of the diseased ducks were collected aseptically for bacterial isolation and culture. The isolated strain was identified as Roseburia murinosa by culture characteristics, staining microscopy, biochemical tests, and 16S rDNA sequence analysis. The results of animal pathogenicity tests showed that the isolated strain had a certain pathogenicity to ducks, and the pathogen that caused the epidemic was Roseburia murinosa from ducks, which was resistant to multiple drugs.

[0004] In the prior art, the invention patent with patent application number CN202110195901.0 provides Roseburia sp. MGB-2, whose deposit number is CGMCC No.1.31010. It has the ability to produce butyrate, and therefore belongs to butyrate-producing bacteria (Faeciroseburia intestinalis). The Roseburia sp. MGB-2 in this patent can significantly control body weight, improve blood sugar, blood lipids and other metabolic syndrome diseases, and can be used to prepare medicines, health products or foods for the treatment of diabetes, lowering blood lipids, obesity and inflammatory bowel disease. However, there is little research on other functions and applications of Roseburia. Summary of the invention

[0005] In view of the problems mentioned in the background technology, the present invention provides a Roseburia and application thereof.

[0006] The above technical objectives of the present invention are achieved through the following technical solutions:

[0007] The invention discloses a Roseburia, which is Rothianasimurium, deposited in the General Microbiology Center of China Microbiological Culture Collection Committee, with the deposit address being Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, with the deposit number being CGMCC No.30097, and the deposit time being March 22, 2024.

[0008] Roseburia, whose sequence is shown in SEQ ID NO:1.

[0009] The present invention also discloses the use of the above-mentioned Rothia in drugs with antibacterial effect, such as being used for preparing drugs with antibacterial effect.

[0010] The metabolites of the Roseburia of the present application are predicted to be three major categories of products: NRPS, betalactone, and lanthipeptide secondary metabolic gene clusters.

[0011] Preferably, Roseburia is used in a drug having an antibacterial effect.

[0012] It is further preferred that the antibacterial effect includes antibacterial effect on one or more of Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium serrata, and Streptococcus non-galactolyticus.

[0013] A bacterial agent comprises the fermentation broth of the above-mentioned Roseburia, which is a solid or liquid bacterial preparation.

[0014] Beneficial Effects

[0015] The present invention discloses for the first time that Rothia nasimurium has antibacterial effects on Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium siccae, and Streptococcus non-galactolyticus, which has a relatively broad prospect for subsequent applications and is convenient for subsequent use in related scientific research. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 This is a morphological picture of Rothia nasimurium under a microscope, 100 times oil immersion microscope examination;

[0017] Figure 2 Phylogenetic tree identified for the 16S rRNA of R. murinciana. DETAILED DESCRIPTION

[0018] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only those obtained by the technicians of the present invention without creative work. All other embodiments belong to the scope of protection of the present invention. Unless otherwise specified, the relevant materials appearing in the subsequent embodiments are prepared by the previous embodiments.

[0019] Example 1

[0020] The invention discloses a Rothia species, which is Rothianasimurium, and is deposited in the General Microbiological Center of China Microbiological Culture Collection Administration, with a deposit number of CGMCC No.30097 and a deposit time of March 22, 2024.

[0021] Roseburia, metabolites are divided into three categories: NRPS, betalactone, and lanthipeptide secondary metabolism gene clusters.

[0022] The Rothia bacteria disclosed in the present invention can be used in the preparation of drugs with antibacterial effects, which specifically include antibacterial effects on one or more of Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium siccae, and Streptococcus nongalactolyticus.

[0023] The sequence of 16s rRNA of Roseburia murinus is shown in SEQ ID NO: 1. The phylogenetic tree of its 16s rRNA identification is shown in Figure 2 shown.

[0024] Through the antibacterial activity determination experiment, a strain of Roseburia with a broad antibacterial spectrum was screened out, which has antibacterial effects on Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium serrata, and Streptococcus lactis.

[0025] Determination of antibacterial activity

[0026] The antibacterial activity of Rothia nasimurium was determined by double-layer agar plate method. Take 5 μL of overnight culture solution of Rothia nasimurium (about 10 7 CFU) was placed in the center of the MHA plate to form an inoculation point with a diameter of 0.5 cm. After inverted culture at 37°C for 24 h, the MHA semi-solid medium cooled to about 55°C after autoclaving was taken and the bacterial suspension of indicator bacteria was added to the concentration of indicator bacteria to about 10 6 CFU / mL (adjust the bacterial solution concentration to 0.5 McFarland turbidity, then add it to MHA semi-solid culture medium and dilute it 100 times), shake it well, slowly cover it on the plate inoculated with the test bacteria, dry it, invert it at 37℃ for 24h, and observe the size of the inhibition zone.

[0027] Table 1 shows the results of the antibacterial experiment on Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, dry Corynebacterium, and non-galactolytic Streptococcus, indicating that Rothianasimurium has an antibacterial effect on Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, dry Corynebacterium, and non-galactolytic Streptococcus. The results are the diameter of the inhibition zone in mm.

[0028] Table 1

[0029]

[0030]

[0031] Note: The test bacteria selected are pathogens from clinically ill livestock and poultry; the inhibition zone is completely transparent.

[0032] Table 2 shows the antibacterial test results of Rothia nasimurium on Streptococcus suis. Rothia nasimurium has a general antibacterial effect on Streptococcus suis. The experimental results are statistically 100% antibacterial. The results are the diameter of the inhibition zone, in mm.

[0033] Table 2 The antibacterial results of Rothia nasimurium against 20 strains of Streptococcus suis

[0034]

[0035]

Claims

1. A Roseburia species, characterized in that: The Roseburia is Rothia nasimurium, which is deposited in the General Microbiology Center of the China Culture Collection Administration. The deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Building 1, Beichen West Road, Chaoyang District, Beijing. The deposit number is CGMCC No.30097 and the deposit date is March 22, 2024.

2. The Roseburia according to claim 1, characterized in that: The sequence is shown in SEQ ID NO:

1.

3. Use of the Roseburia according to claim 1 in a drug with antibacterial effect.

4. The use according to claim 3, characterized in that: The antibacterial effect includes antibacterial effect on one or more of Streptococcus suis, Mycobacterium tuberculosis, Staphylococcus aureus, Corynebacterium siccae, and Streptococcus non-galactolyticus.

5. A bacterial agent, characterized in that: The invention comprises the Rochester bacteria according to claim 1 and / or the fermentation broth of the Rochester bacteria according to claim 1, which is a solid or liquid bacterial preparation.

Citation Information

Patent Citations

  • Roseburia sp. MGB-2 and application thereof

    CN113215020A

  • Rosella rosea for producing FAD-dependent cholesterol oxidoreductase, application, culture medium and preservation method of Rosella rosea for producing FAD-dependent cholesterol oxidoreductase

    CN117025467A